CXCL9 inhibits tumour growth and drives anti-PD-L1 therapy in ovarian cancer
Stefanie Seitz(Technical University of Munich), Holger Bronger(Technical University of Munich)
Cited by 69
Related Papers
Molecular Analysis of HER2 Signaling in Human Breast Cancer by Functional Protein Pathway Activation Mapping
|Clinical Cancer Research|2012|124
Pathological chemotherapy response score is prognostic in tubo-ovarian high-grade serous carcinoma: A systematic review and meta-analysis of individual patient data
|Gynecologic Oncology|2019|121
The Chemokine CX3CL1 Improves Trastuzumab Efficacy in HER2 Low–Expressing Cancer <i>In Vitro</i> and <i>In Vivo</i>
|Cancer Immunology Research|2021|23